SMORODINTSEV RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION

Their core work

The Smorodintsev Research Institute of Influenza is Russia's premier dedicated influenza research institution, operating under the Ministry of Health in St. Petersburg. They maintain curated collections of influenza virus strains and produce biological reference materials — including gold standard diagnostic and research products — that support vaccine development, diagnostic standardization, and outbreak response across the scientific community. As a WHO National Influenza Centre, their core contribution to EU projects has been depositing authenticated virus specimens and derived biological products into the European Virus Archive, enabling validated research materials to flow to laboratories across the continent. Their work underpins the reproducibility and comparability of influenza research within international consortia.

What they specialise in

How they've shifted over time

The institute's keyword profile is unchanged between its two H2020 projects — virus collection, derived products, support to response, and gold standard products appear identically in both EVAg (2015) and EVA-GLOBAL (2020). This is not stagnation but reflects a narrow, stable specialty: they are a dedicated source of authenticated virus materials and that role does not require reinvention. The only meaningful shift is scope — moving from EVAg to its successor EVA-GLOBAL signals the archive's ambitions grew from European to explicitly global, likely broadening the institute's international contacts while keeping their scientific contribution identical.

The institute deepened its commitment to the European Virus Archive infrastructure across a decade, but as a Russian organization its access to Horizon Europe has been suspended since 2022, making future EU collaboration entirely dependent on geopolitical developments.

How they like to work

This institute participates exclusively as a specialist contributor — never as coordinator — in both its H2020 projects. Both EVAg and EVA-GLOBAL were large, multi-partner infrastructure initiatives; together they involved 42 unique partners across 18 countries, reflecting the broad international design of virus archive consortia rather than bilateral relationships. Their role is that of a resource provider: depositing and validating virus strains rather than leading scientific workpackages or driving project governance.

Through just two projects the institute has connected with 42 unique partners spanning 18 countries — a remarkably broad network that reflects the European Virus Archive's design as a continent-wide, multi-node infrastructure rather than targeted bilateral partnerships. No geographic cluster is visible in the data; the network is pan-European by construction.

What sets them apart

The Smorodintsev Institute is Russia's only dedicated influenza research institution with a WHO National Influenza Centre mandate, giving it access to influenza strains circulating in Russia and Central Asia — epidemiologically distinct lineages that Western European institutes cannot source independently. For a consortium building a comprehensive virus archive, this geographic diversity of virus collection is the core value they provide. No Western European institute can replicate their coverage of Eastern European and Russian influenza diversity.

Highlights from their portfolio

• EVAg
  The institute's entry into H2020 through the flagship European Virus Archive project — a continent-scale research infrastructure that became the authoritative EU repository for human and animal viruses, and the project that received the largest share of their EC funding at EUR 56,742.
• EVA-GLOBAL
  Continuation of EVAg with expanded global scope and mandate, confirming that the institute's virus collection contribution was valued enough to carry forward into the next phase of the archive infrastructure through 2024.